es care sales grew across all performance GLP-1 patients and value market share in IO Novo Nordisk ® Number of Patients (millions) 4 3 51.3% 2 1 0 Feb 2020 GLP-1 patients Victoza ® rage na, Hong Kong and Taiwan; RoW: Rest of World Feb 2021 Ozempic ® dulaglutide Value market share 75% 60.1% 60% 37.0% 45% 36.1% 30% 22.0% 2.1% Feb 2022 Rybelsus ® NN GLP-1 15% 0%
Download PDF file